2014
-
Gilead gets 2nd HIV drug approved for PrEP
The FDA approved Gilead Sciences' Descovy for PrEP among male adults and adolescents who are HIV-negative and considered to be at risk.
10/07/2019 -
J&J grabs Bayer exec as new CIO
Johnson & Johnson has hired a former Bayer executive as its chief information officer.
10/07/2019 -
Universities took millions in gifts from Sackler family
Prestigious universities around the world have accepted at least $60 million in donations over the past five years from the family that owns Purdue Pharma, even as the drugmaker became entangled in lawsuits related to the opioid epidemic.
10/04/2019 -
Pharma in review: trending stories 10/4/19
Most popular Pharma Manufacturing stories from the past seven days.
10/04/2019 -
J&J settles Ohio opioid lawsuits for $20.4M
Johnson & Johnson has agreed to a $20.4 million settlement to avoid going to trial over the opioid-addiction crisis in two Ohio counties.
10/03/2019 -
FDA determines toxicity levels in ranitidine ‘unacceptable’
The FDA has changed its story on whether or not the levels of a possible carcinogen in ranitidine are too high.
10/02/2019 -
Trump almost ready to nominate next FDA commish
The Trump administration is reportedly getting set to nominate a new FDA commissioner
10/02/2019 -
FDA rejects AZ lung disease treatment
AstraZeneca announced that the FDA has rejected its new drug application for a chronic obstructive pulmonary disease (COPD) therapy.
10/01/2019 -
Endo drops FDA compounding lawsuit
Endo International announced that it has dropped its case against the U.S. FDA regarding the unlawful compounding of vasopressin from bulk drug substances.
10/01/2019 -
Bangladesh bans ranitidine
With regulatory bodies in the U.S. and EU investigating the presence of a probable carcinogen in ranitidine, Bangladesh has placed an outright ban on the popular heartburn drug.
09/30/2019 -
Sanofi reportedly planning job cuts in Japan
Facing pressure to cut costs, Sanofi is reportedly looking at axing around 200 jobs in Japan.
09/30/2019 -
Novartis gets late stage win for asthma combo
Novartis announced that a Phase 3 trial of QMF149 in patients with uncontrolled asthma has met its primary endpoint.
09/30/2019 -
FTC makes second request in AbbVie, Allergan deal
The U.S. Federal Trade Commission (FTC) has requested more information from AbbVie and Allergan on their $63 billion deal.
09/30/2019 -
Congress clears CDER's Office of New Drugs reorg
The FDA's CDER announced that the reorganization of certain offices within the New Drugs Regulatory Program (NDRP) has been approved by Congress.
09/27/2019 -
Pharma in review: trending stories 9/27/19
Most popular Pharma Manufacturing stories from the past seven days.
09/27/2019 -
Novartis recalls generic Zantac in U.S.
Novartis' Sandoz is now voluntarily recalling all quantities and lots of its prescription ranitidine capsules in the U.S.
09/26/2019 -
Unique pharma art contest crowns its first winner
ACG Group, an integrated pharma manufacturing solutions company, has awarded the first-ever winner to its “Art in a Capsule” competition.
09/25/2019 -
FDA makes first-ever approval of monkeypox vaccine
The FDA has given the greenlight to a Danish drugmaker’s new monkeypox vaccine.
09/25/2019 -
Biocon nabs Pfizer research and development facility
The 60,000 square foot bench-to-pilot scale biologics research facility at TICEL Bio Park in Chennai, India was acquired by the drugmaker's subsidiary Biocon Biologics
09/24/2019 -
Novartis shifts Zolgensma manipulation blame to former AveXis execs
Brian and Allan Kaspar, who were executives at AveXis last year when Novartis acquired it for $8.7 billion, were named by the embattled drugmaker as being responsible for the data mishandling
09/24/2019